In Brief: Guidant/EndoVascular Technologies
This article was originally published in The Gray Sheet
Executive Summary
Guidant/EndoVascular Technologies: EVT shareholders approve Guidant's proposed acquisition of the company, Guidant reports Dec. 19. Announced Oct. 6, the $170 mil. deal calls for an exchange of 0.3154 shares of Guidant for each EVT share ("The Gray Sheet" Oct. 13 I&W-1). Guidant says it issues roughly 2.7 mil. shares in connection with the purchase. EVT CEO Jim Fitzimmons is named a Guidant senior VP and general manager of the company's Cardiac & Vascular Surgery Group, formerly known as the Minimally Invasive Systems Group...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.